Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 2Lymphoma, Non-Hodgkin 2

Interventions

Rituximab 59Cyclophosphamide 35Vincristine 28Doxorubicin 24Prednisone 22Bendamustine Hydrochloride 17Etoposide 15Radiotherapy 12Cytarabine 10Peripheral Blood Stem Cell Transplantation 8Filgrastim 8ibrutinib 7VAP-cyclo protocol 7Prednisolone 7Methotrexate 7Granulocyte Colony-Stimulating Factor 7ibritumomab tiuxetan 6fludarabine 6Melphalan 6Gemcitabine 6pirtobrutinib 5Mitoxantrone 5Lenalidomide 5Carmustine 5Bleomycin 5pixantrone 4Mycophenolic Acid 4Methylprednisolone 4Ifosfamide 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Non-Hodgkin × galiximab × Clear all
NCT00384150 2015-11-26

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00363636 2015-10-02

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
340 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡